{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002092","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.531908+00:00","generated_at":"2026-06-07T02:00:06.724398+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Standard BioTools reports preliminary FY2023 rev $106M; merger closed Jan 5, combined cash >$550M","bullets":["Preliminary Q4 2023 revenue ~$28M and full year ~$106M for Standard BioTools.","SomaLogic preliminary Q4 revenue ~$23M and full year ~$86M.","Core revenue grew >10% YoY; instrument revenue grew >40% YoY.","Merger with SomaLogic completed Jan 5, 2024; combined cash >$550M as of Dec 31, 2023.","Company to report full Q4 and FY2023 results in early March with 2024 outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002092","json":"https://secwatch.observer/filing/0001104659-24-002092.json","markdown":"https://secwatch.observer/filing/0001104659-24-002092.md","text":"https://secwatch.observer/filing/0001104659-24-002092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/tm2333984d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:00:06.724398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40270975c6c6f1727268f3d46c4ec2aecf08d98b","claim":"STANDARD BIOTOOLS INC. reported fourth quarter 2023 results: revenue approximately $28 million.","evidence_excerpt":"Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"approximately $28 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"a29c1a0c46fa36a17db814bce0d4d5b70adc8a10","claim":"STANDARD BIOTOOLS INC. reported full year 2023 results: revenue approximately $106 million.","evidence_excerpt":"full year 2023 revenue of approximately $106 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000110465924002092/0001104659-24-002092-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"approximately $106 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}